Skip Navigation

European Heart Journal 2004 25(23):2164-2166; doi:10.1016/j.ehj.2004.09.031
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schellekens, S.
Right arrow Articles by Verheugt, F. W.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schellekens, S.
Right arrow Articles by Verheugt, F. W.A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Special ESC report

Hotline sessions of the 26th European Congress of Cardiology

Stefanie Schellekens and Freek W.A. Verheugt*

Department of Cardiology, University Medical Centre Nijmegen, St. Radboud, Heartcentre, 540 Cardiology, P.O. Box 9101, 6500 Nijmegen HB, The Netherlands

* Correspondence to: Professor Freek W.A. Verheugt, Department of Cardiology, University Medical Centre Nijmegen, St. Radboud, Heartcentre, 540 Cardiology, P.O. Box 9101, 6500 Nijmegen HB, The Netherlands. Tel.: +31 2436 14220/14533; fax: +31 2435 40537 (E-mail: f.verheugt@cardio.umcn.nl).

The first 150 words of the full text of this article appear below.

Of the 12 presentations at the three Hotline sessions of the 26th European Congress of Cardiology, held in Munich, Germany, 27 August–1 September 2004, nine will be summarized here, as the other three have been published in the mean time: the ACTION trial ( Lancet 2004;364:849–57[CrossRef][Web of Science][Medline]), the INTER-HEART study ( Lancet 2004;364:937–52[CrossRef][Web of Science][Medline]) and the A to Z trial ( JAMA 2004;292:1307–16).[Abstract/Free Full Text] The authors of this summary collected the information given during the presentation of the studies and, therefore, this report only shows preliminary results.

During the first Hotline session, two new studies on prevention and medical treatment were presented.

Dr. T. Lüscher from Zürich, Switzerland presented the ENCORE-2 study: a randomized, placebo-controlled, angiographic and intravascular ultrasound (IVUS) trial, in which the 18–24 months effects of nifedipine gastrointestinal therapeutic system (GITS) 30–60 . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BMJHome page
G. Cocco and D. Chu
Rimonabant may induce atrial fibrillation
BMJ, June 12, 2009; 338(jun12_1): b1061 - b1061.
[Full Text]

Home page
 The Annals of PharmacotherapyHome page
K. M Dale and C M. White
Dronedarone: An Amiodarone Analog for the Treatment of Atrial Fibrillation and Atrial Flutter
Ann. Pharmacother., April 1, 2007; 41(4): 599 - 605.
[Abstract] [Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
M. J. Tafreshi and J. Rowles
A Review of the Investigational Antiarrhythmic Agent Dronedarone
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 15 - 26.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
R. P. Giugliano and E. Braunwald
The Year in Non--ST-Segment Elevation Acute Coronary Syndromes
J. Am. Coll. Cardiol., September 6, 2005; 46(5): 906 - 919.
[Full Text] [PDF]